Full Year Results, Appendix 4E and Analysts Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- CSL Settles US Class Action and Updated Profit Guidance
- Half Yearly Report and Accounts
- Appendix 4E, FY Results and Analysts Presentation
- Changes relating to buy-back - Appendix 3D
- IDELVION(R) (rFIX-FP) - FDA approval
Later from CSL
- New US$500 million Private Placement
- Appointment of Paul Perreault as Executive Director
- Announcement of buy-back
- Chairmans and MDs address to shareholders
- Recombinant Technologies
Follow CSL into a list and get an email when it puts out news.
Follow CSL